[Boston, 18th June 2025] – The global neurorehabilitation devices market is projected to surge from USD 2.1 billion in 2023 to USD 14.3 billion by 2035, growing at a CAGR of 21.3%, according to Clearview Market Insights. This growth is driven by demand for stroke rehabilitation, trends in home-based care, and AI-powered personalized therapy.
Request Sample @ https://clearviewmarketinsights.com/report-details/global-neurorehabilitation-devices-market/
Key Growth Catalysts
- Stroke Epidemic:
- 15 million annual cases worldwide (2030 estimate); robotic gait trainers can reduce recovery time by 40%.
- BCIs enable paralyzed patients to communicate using brain signals (90% accuracy in trials).
- Home Healthcare Boom:
- Neuroelectrics’ Starstim becomes the first FDA-cleared home-use tDCS device (2025).
- 50% of patients now opt for telerehab post-discharge.
- Military/VA Adoption:
- Ekso Bionics’ exoskeletons deployed in 50+ VA hospitals (2025).
Competitive Intensity
- Hocoma (30% share): Dominates with Lokomat Pro, now improved with real-time AI analytics.
- MindMaze (startup): VR neurorehab games attract USD 200M in funding.
Regional Leaders
- North America (XX%): U.S. accounts for 60% of robotic device sales.
- Asia-Pacific (20%): Japan’s stroke rehab centers adopt hybrid exoskeletons.
Future Milestones
- 2026: First cloud-based rehab platform with FDA approval.
- 2028: BCIs enter mainstream for locked-in syndrome.
- 2030: 70% of rehab occurs at home via AI-guided devices.
For more insights, visit https://clearviewmarketinsights.com/
About Clearview Market Insights:
Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369
